Express Scripts knocks many newer brands off formulary

Share this article:

Express Scripts, the big PBM, issued its new formulary for 2014, and a list accompanying the formulary shows many recently approved brands won't be covered, reports FiercePharma. Among those being excluded from reimbursement: Pfizer RA drug Xeljanz, Johnson & Johnson psoriasis treatment Stelara, and  GlaxoSmithKline respiratory drug Breo Ellipta. Alternatives are listed beside each.

It's the first time the PBM's preferred formulary designates certain drugs as “not covered,” an Express Scripts spokesman told FiercePharma, adding "Drug choices in some classes are larger than ever, with many products costing more with no additional health benefit."

The co-pay card, a marketing tactic often used by pharma to provide patient assistance for branded drugs, played into Express Scripts's decision, FiercePharma points out.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.